U of M Biomedical Researchers Create Artificial Human Bone Marrow

ANN ARBOR, Mich.- Artificial bone marrow that can continuously make red and white blood cells has been created in a University of Michigan lab.
This development could lead to simpler pharmaceutical drug testing, closer study of immune system defects and a continuous supply of blood for transfusions.
The substance grows on a 3-D scaffold that mimics the [.. more ..]

U-M to Buy Pfizer’s Former Ann Arbor Property

ANN ARBOR, Mich.-In a move that will directly create at least 2,000 jobs during the next decade and accelerate expansion of the University of Michigan’s research activities critical to the state’s economic development, the U-M Board of Regents today approved the purchase of the Ann Arbor property of pharmaceutical firm Pfizer Inc.
In time, U-M anticipates [.. more ..]

HealthMedia Named “Company of the Year”

ANN ARBOR, MICH. - December 15,2008 - HealthMedia, Inc., the pioneer in applying advanced technology to emulate a health coaching session via the web - without the coach - for wellness, behavioral health, disease management, aging well, and medication adherence, continues to be acknowledged as a leader in business and healthcare innovation with several recent [.. more ..]

Michigan Firm Rolls out DNA Testing to Help Drug Inventors Get to Market

The Ann Arbor-based Michigan Technology and Research Institute Wednesday announced the launch of its DNA testing for human clinical trials, with an emphasis on inflammatory diseases and mechanistic studies of adverse drug reactions.
Using DNA-based methods to identify clinically-important variations in coding for immune cell proteins (cytokines), MITRI will enhance new drug development in the rapidly [.. more ..]

Researcher Receives Free Flow Cytometer System as First Winner of Accuri Flow Cytometer Creativity Awards Program

ANN ARBOR, Mich., December 11, 2008 - Accuri Cytometers Inc., a life sciences company developing revolutionary bench-top flow cytometer systems, today announced the first recipient of its Accuri Flow Cytometer Creativity Awards Program.. Heather Newkirk, Ph.D., Executive Director of Business Development and Quality Assurance/Regulatory Affairs at Clinical Reference Laboratory, Inc. and an Assistant Professor of [.. more ..]

Compendia Bioscience Lands $3 Million in Venture Capital

Compendia Bioscience plans to use $3 million in newly acquired venture capital to create another 20 jobs in Ann Arbor, more than doubling its current staff.
Most of that $3 million, $1.75 million of it, comes from Michigan’s 21st Century Jobs Fund. The rest is matching funds the bio IT firm has raised on its own.
Compendia [.. more ..]

HealthMedia Announces First Individually Tailored Physical Activity Intervention Program

ANN ARBOR, MICH. - November 24, 2008 - HealthMedia, Inc., the pioneer in applying advanced technology to emulate a health coaching session via the web - without the coach - for wellness, disease management, behavioral health, medication adherence, and aging well, has introduced one of its most comprehensive product and service releases. The new release [.. more ..]

Aastrom Announces Treatment of First Patient in U.S. Phase II IMPACT-DCM Trial

ANN ARBOR, Mich., Nov. 20, 2008 (GLOBE NEWSWIRE) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the first patient has been treated in its randomized, controlled, prospective, open-label IMPACT-DCM clinical trial. Currently enrolling patients at The Methodist Hospital in Houston, TX, Baylor University Medical Center in Dallas, TX and The [.. more ..]

Cielo MedSolutions Releases First Embeddable Web Service for Clinician Prompts

Ann Arbor, MI (November 12, 2008) - Cielo MedSolutions, a provider of healthcare software and web applications, today announced the addition of Web services to its Cielo ClinicTM clinical quality management system software-as-a-service (SaaS) offering. The new Web services capability is already in beta test in a multi-site, multi-specialty clinical environment.
The addition of Web services [.. more ..]

Aastrom Announces Achievement of Milestone in U.S. Phase IIb Critical Limb Ischemia Clinical Trial

ANN ARBOR, Mich., Oct. 30, 2008 (GLOBE NEWSWIRE) — Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading regenerative medicine company, today announced that the 30th patient has been treated in the Company’s U.S. Phase IIb RESTORE-CLI clinical trial. This milestone marks the first step toward interim data retrieval from this clinical trial evaluating Aastrom’s Vascular Repair Cells [.. more ..]

Who links to my website?